Korean J Transplant.  2023 Nov;37(Suppl 1):S28. 10.4285/ATW2023.F-5956.

Impact of denosumab on aortic arch calcification in kidney transplant recipients

• Park WY
• Yang J
• Kwon JK
• Lee HJ
• Kim Y
• Paek JH
• Jin K
• Han S

• KMID: 2551602
• DOI: http://doi.org/10.4285/ATW2023.F-5956

Abstract

Background
Aortic arch calcification (AoAC) is associated with cardiovascular disease in kidney transplant recipients (KTRs). Recent research reported that Denosumab, a potent antiresorptive agent, might affect to AoAC in hemodialysis patients, but the impact of denosumab on AoAC in KTRs remain unclear.
Methods
We analyzed 45 KTRs who used denosumab for the treatment of osteoporosis from 2018 to 2023. Denosumab was administered to KTRs every 6 months. AoAC was semiquantitatively estimated by calculating calcification score. We investi-gated the change of AoAC by simple chest X-ray, biochemical parameters, cardiovascular event, graft failure and patient death.
Results
The mean age was 50.6±10.1 years. The mean AoAC score at 1-year postdenosumab was significantly decreased comparing to the mean AoAC score at pr-denosumab (18.1±20.8 vs. 20.8±23.4, P=0.025). There were no significant differences in the calcium, phosphorus, parathyroid hormone, vitamin D, creatinine and tacrolimus trough levels between pre- and postdenosumab. Cardiovascular event did not occur in the study population. There were no significant difference of graft failure and death in KTRs.
Conclusions
The use of denosumab might be effective to improve AoAC in KTRs.